Novo Nordisk's Expanding GLP-1 Portfolio Tests Formulation Limits

Novo Nordisk is set to present 52 abstracts at the European Congress on Obesity (ECO 2026), 12-15 May in Istanbul, Turkey, spanning four distinct semaglutide programmes. The breadth of that dataset signals accelerating formulation complexity across the portfolio, with oral, higher-dose, and combination modalities each carrying distinct manufacturing and regulatory implications for API suppliers and contract development and manufacturing organisations.

The data package covers Wegovy (semaglutide 2.4 mg), the higher-dose semaglutide 7.2 mg from the STEP UP trial, the oral semaglutide 25 mg (Wegovy pill) from the OASIS 4, ORION, and OPTIC programmes, and CagriSema, an investigational fixed-ratio combination of cagrilintide 2.4 mg and semaglutide 2.4 mg described as a first-in-class GLP-1 receptor agonist and long-acting amylin analogue combination. Each formulation variant demands differentiated process validation strategies and, in the case of the oral tablet, distinct bioavailability and dissolution controls not required for subcutaneous presentations.

• Post-hoc analyses from STEP UP will examine early responder profiles and time-to-threshold weight reduction with semaglutide 7.2 mg, data relevant to dose titration protocol design.
• OASIS 4 post-hoc data will address early responders to oral semaglutide 25 mg and efficacy in patients with poor physical function, informing label expansion considerations.
• Real-world evidence from the OUTSTEP 1 interim analysis will characterise patient characteristics and experiences with injectable semaglutide, with implications for pharmacovigilance and post-market surveillance planning.
• SELECT trial data will examine the impact of semaglutide 2.4 mg on major adverse cardiovascular events in perimenopausal and postmenopausal women with obesity and cardiovascular disease.

CagriSema's presence in the ECO 2026 programme is particularly consequential for manufacturers tracking next-generation obesity pipeline timelines. A fixed-dose combination of two long-acting peptide analogues introduces co-formulation stability requirements and dual-API characterisation obligations under ICH Q10 quality system frameworks, raising the technical bar for any CDMO seeking to participate in commercial-scale supply. Novo Nordisk's chief scientific officer and head of Research and Development, Martin Holst Lange, stated the company looks forward to "presenting compelling data at ECO" and to "supporting women and all patients suffering from obesity."

Source: Novo Nordisk press release via GlobeNewswire, 28 April 2026.